| Ytd | -37.82% | |
| 1y | 16.43% |
| Open | 5.50 | Prev Close | 5.48 | Low | 5.50 | High | 5.50 | Mkt Cap | 329.54M |
| Vol | 10.67K | Avg Vol | 1.01M | EPS | -2.12 | P/E | -2.58 | Forward P/E | 23.40 |
| Beta | 0.60 | Short Ratio | 4.85 | Inst. Own | 78.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 6.08 | 200-d Avg | 6.53 | 1yr Est | 10.43 |
VNDA News
This marks the first time the EMA has granted orphan drug designation recognition for a drug to trea
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today an
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Adminis
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ann
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ann
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeli
WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today anno
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.82 per share versus the Zacks Cons
Fanapt ® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-b
The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While thi
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 1, 2026 /PRNewswire/ -- Vanda
Conference Call and Webcast to Follow WASHINGTON, April 29, 2026 /PRNewswire/ -- Vanda Pharmaceutica
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today a
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estim
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today a
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report)'s share price crossed above its 200-day
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) was the target of a significant growth i
Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Atrinsic (NASDAQ: PTIX - Get Free Report)
Editor’s Note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the he
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quart
On Tuesday, 647 companies set new 52-week lows.
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
On Friday, 209 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday